Inmed Pharmaceuticals Ltd., a Canadian-listed start-up mixing cannabinoids and noncannabis elements for the treatment of glaucoma, pain and inflammation is working to move into the clinic this year and attract the kind of big pharma backers that have rallied to support high-profile cannabinoid drugmaker GW Pharmaceuticals plc.